CARB-X invests up to $11m in Microbion

CARB-X is investing up to $11m into US-based Microbion to develop its inhaled drug pravibismane to treat cystic fibrosis.

CARB-X is awarding Microbion Corporation of Bozeman, MT, USA, up to $6.1 million plus up to $5.4 million more if certain project milestones are met, to develop its anti-infective drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.

Read more: https://carb-x.org/carb-x-news/carb-x-funds-microbion-to-develop-inhaled-drug-to-treat-cystic-fibrosis-related-lung-infections/